BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16568472)

  • 1. Prognostic impact of molecular markers in a series of 220 primary glioblastomas.
    Houillier C; Lejeune J; Benouaich-Amiel A; Laigle-Donadey F; Criniere E; Mokhtari K; Thillet J; Delattre JY; Hoang-Xuan K; Sanson M
    Cancer; 2006 May; 106(10):2218-23. PubMed ID: 16568472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features.
    Benito R; Gil-Benso R; Quilis V; Perez M; Gregori-Romero M; Roldan P; Gonzalez-Darder J; Cerdá-Nicolas M; Lopez-Gines C
    Neuropathology; 2010 Aug; 30(4):392-400. PubMed ID: 20051017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic stratification of patients with anaplastic gliomas according to genetic profile.
    Dehais C; Laigle-Donadey F; Marie Y; Kujas M; Lejeune J; Benouaich-Amiel A; Pedretti M; Polivka M; Xuan KH; Thillet J; Delattre JY; Sanson M
    Cancer; 2006 Oct; 107(8):1891-7. PubMed ID: 16986124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression.
    Hoang-Xuan K; He J; Huguet S; Mokhtari K; Marie Y; Kujas M; Leuraud P; Capelle L; Delattre JY; Poirier J; Broët P; Sanson M
    Neurology; 2001 Oct; 57(7):1278-81. PubMed ID: 11591848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
    Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
    J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular genetic alterations in glioblastomas with oligodendroglial component.
    Kraus JA; Lamszus K; Glesmann N; Beck M; Wolter M; Sabel M; Krex D; Klockgether T; Reifenberger G; Schlegel U
    Acta Neuropathol; 2001 Apr; 101(4):311-20. PubMed ID: 11355302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation among pathology, genotype, and patient outcomes in glioblastoma.
    Homma T; Fukushima T; Vaccarella S; Yonekawa Y; Di Patre PL; Franceschi S; Ohgaki H
    J Neuropathol Exp Neurol; 2006 Sep; 65(9):846-54. PubMed ID: 16957578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No association of MDM2 SNP309 with risk of glioblastoma and prognosis.
    El Hallani S; Marie Y; Idbaih A; Rodero M; Boisselier B; Laigle-Donadey F; Ducray F; Delattre JY; Sanson M
    J Neurooncol; 2007 Dec; 85(3):241-4. PubMed ID: 17568997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic analyses for predictors of radiation response in glioblastoma.
    Shih HA; Betensky RA; Dorfman MV; Louis DN; Loeffler JS; Batchelor TT
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):704-10. PubMed ID: 15978739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations of TP53, amplification of EGFR, MDM2 and CDK4, and deletions of CDKN2A in malignant astrocytomas.
    Biernat W; Debiec-Rychter M; Liberski PP
    Pol J Pathol; 1998; 49(4):267-71. PubMed ID: 10323080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene amplification as a prognostic factor in primary brain tumors.
    Olson JJ; Barnett D; Yang J; Assietti R; Cotsonis G; James CD
    Clin Cancer Res; 1998 Jan; 4(1):215-22. PubMed ID: 9516974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of genotype and morphology on the prognosis of glioblastoma.
    Schmidt MC; Antweiler S; Urban N; Mueller W; Kuklik A; Meyer-Puttlitz B; Wiestler OD; Louis DN; Fimmers R; von Deimling A
    J Neuropathol Exp Neurol; 2002 Apr; 61(4):321-8. PubMed ID: 11939587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
    Ruano Y; Ribalta T; de Lope AR; Campos-Martín Y; Fiaño C; Pérez-Magán E; Hernández-Moneo JL; Mollejo M; Meléndez B
    Am J Clin Pathol; 2009 Feb; 131(2):257-63. PubMed ID: 19141386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
    McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
    Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary and secondary glioblastomas: from concept to clinical diagnosis.
    Kleihues P; Ohgaki H
    Neuro Oncol; 1999 Jan; 1(1):44-51. PubMed ID: 11550301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years.
    Korshunov A; Sycheva R; Golanov A
    Cancer; 2005 Aug; 104(4):825-32. PubMed ID: 15981281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
    Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic pathways to glioblastoma: a population-based study.
    Ohgaki H; Dessen P; Jourde B; Horstmann S; Nishikawa T; Di Patre PL; Burkhard C; Schüler D; Probst-Hensch NM; Maiorka PC; Baeza N; Pisani P; Yonekawa Y; Yasargil MG; Lütolf UM; Kleihues P
    Cancer Res; 2004 Oct; 64(19):6892-9. PubMed ID: 15466178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker.
    Harada K; Kurisu K; Tahara H; Tahara E; Ide T; Tahara E
    J Neurosurg; 2000 Oct; 93(4):618-25. PubMed ID: 11014540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.